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Introduction: Cardiovascular involvement represents the leading cause of mortality in SLE
patients. Its most common manifestations include pericarditis, valvular affections, conduc-
tion disorders, and arterial hypertension. Pulmonary hypertension and coronary arteritis are
seen less often. Venous thrombosis directly related to SLE affects about 10% of SLE cases.
Acceleration of atherosclerosis is very important and so are the ensuing cardiocerebral
events, the most common of these being myocardial infarctions (MIs), cerebrovascular
events, thromboembolic events (TEs), heart failure, and sudden death. We analyzed the
frequency of cardiovascular events and their relationship to selected risk factors in a cohort
of SLE patients followed in a single clinical center.
Methods: The studied population comprised 63 SLE patients (women: men = 53: 10, mean age
38.4  12.7 years, mean disease duration 143  82 months, BMI 24.74  5.06, waist circum-
ference 83.38  16.58 cm), including 25 patients with lupus nephritis. Intima-media thick-
ness (IMT) was assessed ultrasonographically  in a standard manner. Of laboratory values,
serum concentrations of total cholesterol (TC), triglycerides (TG), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), anti-ds-DNA, antinucleosomal antibodies (ANUC),
complement components C3 and C4, and ENA antibodies were measured. Clinical disease
activity was assessed using indices of activity and cumulative damage such as SLEDAI and
SLICC. Screening for traditional cardiovascular risk factors was based on appropriate ques-
tionnaires. Detailed analysis was employed to calculate cumulative doses of glucocorticoids
and other immunosuppressants  and to evaluate the use of anticoagulants, antiaggregants,
statins, and ACE inhibitors.
Results: A total of 21 (33%) patients had a history of cardiovascular event during the course of
their SLE: there were 3 myocardial infarctions (4.7% of the entire population, 14% of all
cardiovascular events), 8 cerebrovascular events (12.7%, resp. 38%), and 12 thromboembolic
events (19%, resp. 57%). In two patients, two different manifestations of cardiovascular
involvement were combined – cerebrovascular event and MI in one, cerebrovascular event
and TE event in the other. Cardiovascular events correlated with obesity, waist and hip
circumference, smoking, total cholesterol, LDL, TC/HDL ratio, and apolipoproteins A-1 and B.
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Borderline statistical signiﬁcance was noted for disease activity, hsCRP, positivity of RNP
and anticardiolipin antibodies, lupus anticoagulant ( p = 0.06) and intima-media thickness
( p = 0.07). Subgroups of patients with cardiovascular event and arterial hypertension were
also analyzed in more detail.
Conclusion: In this article, we point to the high rate of cardiovascular events in SLE patients,
thus conﬁrming the need to pay appropriate attention to cardiovascular problems in the
ﬁeld of rheumatology.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
inﬂammatory disease affecting mainly women of fertile age.
It is characterized by hyperactivity of B-cells and by overpro-
duction of autoantibodies without organ speciﬁcity, many of
which contribute to the formation of immunocomplexes.
Their deposition in tissues and blood vessels results in
inﬂammatory organ impairment. The clinical picture of SLE
is very variable. SLE is a highly heterogeneous disease, which
can be divided into many subtypes deﬁned clinically or based
on laboratory ﬁndings; SLE can also overlap with many other
diagnostic entities (mixed connective tissue disease, Sjögren's
syndrome, and antiphospholipid syndrome). The disease
course is characterized by a series of remissions and
exacerbations. As for the laboratory ﬁndings in SLE, production
of autoantibodies without organ speciﬁcity aimed at nuclear,
cytoplasmic, and surface antigens of the patient's body is
typical. Acute disease ﬂares are usually accompanied by
systemic signs, such as fever, fatigue and weight loss. The
most common SLE manifestations include involvement of
skin, joints, cardiovascular system, lungs, renal glomeruli,
central nervous system or hematopoiesis. SLE can result in
failure of the involved organs, severe forms of SLE thus being
associated with signiﬁcant mortality.
Cardiovascular mortality represents one of the leading
causes of death in SLE patients [1] (Graph 1).29.6
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Graph 1 – Death causes in SLE patients, study wiCardiovascular manifestations of SLE can be divided into
the following [2,3]: valvular and pericardial involvement,
myocardial dysfunction, conduction disorders, accelerated
atherosclerosis and thromboembolic disease. Pulmonary
hypertension and coronary arteritis are seen less often [4].
Venous thrombosis directly related to SLE affects about 10% of
SLE patients [5]. Cardiovascular involvement is present in up to
50% cases [6]. Despite its initially asymptomatic course,
cardiovascular involvement is associated with increased
morbidity and mortality of SLE patients. The most common
SLE-related cardiovascular events include myocardial infarc-
tions (MIs), cerebrovascular events, thromboembolic events
(TEs), heart failure, and sudden death. Pathogenesis of
cardiovascular impairment in SLE is variable. Traditional risk
factors for atherosclerosis, inﬂammatory nature of autoim-
mune SLE, antibodies, acceleration of endothelial dysfunction,
and – last but not least – SLE therapy all play a role here [7].
Speciﬁc antibodies cause oxidation of LDL particles, thus
accentuating their atherogenic effect, or exert a negative
inﬂuence on the character of physiologically protective HDL
particles. Endothelial dysfunction within the vascular system
ensues, increasing its vulnerability, afﬁnity to lipoproteins and
activity of enzymes accelerating the development of athero-
sclerosis [8].
We analyzed the frequency of cardiovascular events and
their relationship to selected risk factors in a cohort of SLE
patients followed in a single clinical center (Third Department7.7 7.4
lar diseases renal failure other
th 5 years of follow-up (data shown as %, 1).
Fig. 1 – Ultrasonographic assessment of IMT in the common
carotid artery.
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crinology; Faculty Hospital of Palacký University, Olomouc).
Methods
We present a retrospective study with a cross-sectional
analysis of cardiovascular SLE manifestations and their
relationship to the disease activity, index of impairment,
traditional risk factors for atherosclerosis, and intima-media
thickness. Associations with medication were also sought.
The studied population included patients fulﬁlling the ACR
(American College of Rheumatology) criteria for SLE [9]. The
inclusion criteria were as follows: diagnosis of SLE and without
cardiovascular disease (CVD) impairment before the diagnosis
of SLE was established. There were 63 patients in our
population, 54 women and 9 men, their mean age being
38.4  12.7 years (range: 18–72 years) and mean disease
duration 143.0  173.5 months (range: 0–342 months). The
diagnosis of SLE was made at a mean age of 28.0  12.0 years
(median: 25.0, min 9, max 60) in this cohort.
The patients were examined between September 2010 and
December 2011. Data were obtained using questionnaires,
detailed analysis of personal and pharmacological history,
laboratory tests, and ultrasonographic measurement of inti-
ma-media thickness in the carotid arteries [10]. The patients
were then divided then into two groups: one with CVD and the
other without CVD. Cardiovascular events included myocar-
dial infarctions, ischemic or thromboembolic cerebrovascular
accidents, and thromboembolic events.
By analyzing the patients' medical records, we determined
the duration of their illness and cardiovascular disease (or its
absence); risk-conferring comorbidities such as hypertension
or diabetes mellitus were also noted, as was family history of
early manifestations of cardiovascular problems. Moreover,
the patients were divided according to the presence or absence
of lupus nephritis, which is considered a signiﬁcant risk factor
for premature atherogenesis. Neurolupus manifestation was
also considered as a risk factor. Patients meeting the criteria of
The American College of Rheumatology nomenclature and
case deﬁnitions for neuropsychiatric lupus syndromes were
included [11]. Postmenopausal status was monitored, too.
Other manifestations of SLE are not connected with higher risk
of cardiovascular disease. Cumulative and mean daily doses of
glucocorticoids and individual immunosuppressants (cyclo-
phosphamide, cyclosporine A, azathioprine, mycophenolate
mofetil, sulfasalazine, methotrexate, and hydroxychloro-
quine) were calculated, too. Current use of antiaggregants,
anticoagulants, ACE inhibitors, and statins was recorded from
the patients' documentation.
The presence of traditional risk factors (smoking, inade-
quate consumption of vegetables and fruits, low level of
physical activity) was assessed using questionnaires. BMI was
determined for each patient, and so were the waist and hip
circumferences [12].
Disease activity was evaluated using the SLE Disease
Activity Index (SELENA SLEDAI) and the damage index was
quantiﬁed by the Systemic Lupus International Collaborating
Clinics/American College of Rheumatology (SLICC/ACR) scale
[13,14].Current activity of antibodies (ANA – antinucleolar anti-
bodies, anti-ds-DNA, antinucleosomal antibodies, ENA anti-
bodies – anti-SS-Ro, anti-SS-La, Sm, RNP, anticardiolipin
antibodies, lupus anticoagulant), concentration of comple-
ment components C3 and C4, and circulating immunocom-
plexes were determined. Renal functions were characterized
by glomerular ﬁltration rate (GFR, calculated according to the
Modiﬁcation of Diet in Renal Disease – MDRD – formula) and
creatinine and urea concentrations.
Lipid spectrum analysis comprised the total cholesterol,
triglycerides (TG), HDL- and LDL-cholesterol, apolipoprotein A-
1, apolipoprotein B, and lipoprotein (a). High-sensitivity C-
reactive protein (hsCRP) was also measured.
Intima-media thickness in both carotid arteries was
evaluated ultrasonographically in each patient (Fig. 1).
The above parameters were analyzed in the entire group of
patients with CVD and also in subgroups of patients with a
history of myocardial infarction, cerebrovascular event,
thromboembolic disease or arterial hypertension.
Descriptive statistics, Student's t-test, and Pearson's corre-
lation coefﬁcient were employed in the statistical analysis.
Results
Cardiovascular disease during the course of SLE was noted in
21 patients (33%) – there were 3 myocardial infarctions (4.7% of
the entire population, 14% of all cardiovascular events), 8
cerebrovascular events (12.7% of the entire population, 38% of
all cardiovascular events), and 12 thromboembolic events (19%
of the entire population, 57% of all cardiovascular events). In
two patients, two different manifestations of cardiovascular
involvement were combined – cerebrovascular event and MI in
one, and cerebrovascular and TE event in the other. The mean
age of ﬁrst CVD manifestation in the whole group was 38.15
years. Disease duration at the time of ﬁrst CVD was 8.01 years,
so CVD was a late complication of SLE. Four patients (19%) had
CVD in the ﬁrst year of disease. CVD was manifested at the
time of diagnosis in three patients.
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patients with neurolupus (25.4%) and 17 patients with
secondary antiphospholipid syndrome (26.9%) in the studied
population. Five patients suffered from diabetes mellitus
(7.9%), 25 patients were diagnosed with and treated for
hypertension, 10 women were postmenopausal, 3 patients
had a family history of early cardiovascular disease in a ﬁrst-
grade relative (before the age of 55 years in men, before the age
of 60 years in women; one myocardial infarction and two
cerebrovascular events were recorded–4.7%).
Twenty-eight patients had BMI above 25 (16 respondents
were overweight – 25.4%, 12 were obese – 19%; 44% in total),
while 16 women and 3 men had risky waist circumference
values (above 88 cm in women, above 102 cm in men, 11).
Using questionnaires, we found 26 smokers or ex-smokers
who abandoned smoking less than 5 years ago (41.3%); 27
patients described themselves as absolute abstinents, 4
admitted consuming more alcohol than the recommended
daily dose (42.9% and 6.3%, respectively). Inadequately low
level of physical activity (30 minutes of aerobic exercise 5 times
a week being recommended) was mentioned by 43 patients, i.e.
68.3%. Low intake of vegetables and fruits (less than 3 kg a
week) was noted in 40 patients (66.7%).
Patients with cardiovascular disease (n = 21)
Tables 1 and 2 show the proﬁles of patients with and without
CVD, respectively. The rate of cardiovascular events was
slightly higher (the difference almost reaching statisticalTable 1 – Relationship between cardiovascular disease during 
sex, and disease duration.
With a card
disea
n 21
Age (years) 40.3
Sex (men: women) 5:1
Disease duration (months) 181.
Age at diagnosis (years) 30.0
Hypertension (n, %) 8 
Lupus nephritis (n, %) 8 
Neurolupus (n, %) 14 
Diabetes mellitus (n, %) 2 
Postmenopausal women (n, %) 3 
Antiphospholipid syndrome 12 
Family history of cardiovascular disease (n, %) 1 
Age of ﬁrst CVD (years) 38.1
Disease duration at the time of ﬁrst CVD (years) 8.0
Waist circumference (cm) 89.0
Hip circumference (cm) 104.
BMI 26.2
Smokinga (n, %) 11 
Vegetablesb (n, %) 12 
Physical activityc (n, %) 9 
Alcohold (n, %) 8 + 1 
a Smoking – current smoking or smoking quitted less than 5 years ago.
b Vegetables – vegetable and fruit intake less than 3 kg a week.
c Physical activity – aerobic exercise less than 30 minutes 5 times a wee
d Alcohol – absolute abstinents + patients using more than the recommesigniﬁcance; p = 0.06) in male patients. History of predeﬁned
cardiovascular disease correlated with obesity, waist and hip
circumference, and smoking. Lipid spectrum alterations –
namely those concerning the total cholesterol, LDL, TC/HDL
ratio, low levels of apolipoprotein A-1 and high levels of
apolipoprotein B – were also signiﬁcantly associated with
cardiovascular disease. Some, albeit statistically non-signiﬁ-
cant, differences were found in disease activity (SLEDAI),
hsCRP concentration, positivity of RNP antibodies, antic-
ardiolipin antibodies, and lupus anticoagulant ( p = 0.06). The
level of complement components C3 and C4 was signiﬁcantly
higher in patients with cardiovascular disease. As for the
intima-media thickness, the difference between both the
groups was just borderline ( p = 0.07). Patients with cardiovas-
cular disease are signiﬁcantly more often treated with statins
and anticoagulants and their cumulative dose of cyclophos-
phamide was higher.
Patients with arterial hypertension (n = 25)
Several signiﬁcant risk factors for hypertension were found:
lupus nephritis, risky waist circumference, BMI above 30, and
treatment with cyclosporine A.
Patients with a history of myocardial infarction (n = 3)
Any statistical comparison concerning this small subgroup of
patients has to be interpreted cautiously. However, patients
with a history of MI had a signiﬁcantly higher cumulativethe course of SLE and selected traditional risk factors, age,
iovascular
se
Without cardiovascular
disease
p
 42
8 37.38 NS
6 4: 38 0.06
51 123.98 NS
2 27.05 NS
38.1 17 40.5 NS
38.1 17 40.5 NS
66.7 2 4.8 <0.001
9.5 3 7.1 NS
18.8 7 18.4 NS
57.1 5 11.9 <0.001
4.8 2 4.8 NS
5
1
7 80.54 0.02
14 96.59 0.007
0 24.08 0.05
52.4 10 23.8 0.01
57.1 28 66.7 NS
42.9 22 52.4 NS
38.1 + 4.8 24 + 1 57.1 + 2.4 NS
k.
nded daily dose.
Table 2 – Relationship between cardiovascular disease and disease activity, lipid and immunological profile, intima-media
thickness, and treatment.
With a history of
cardiovascular event
Without history of
cardiovascular event
p
Disease activity
SLICC 1.52 1 NS
SLEDAI 8.67 6.5 0.06
hsCRP (g/l) 6.79 4.32 0.06
Creatinine (mmol/l) 71.71 71.12 NS
Glomerular ﬁltration rate (ml/s) 1.55 1.60 NS
Lipid proﬁle
Total cholesterol (mmol/l) 6.07 5.01 0.05
Triglycerides (mmol/l) 1.93 1.62 NS
HDL (mmol/l) 1.28 1.42 NS
LDL (mmol/l) 3.39 2.84 0.02
CH/HDL ratio 6.23 3.72 0.02
Apo lipoprotein A-1 (g/l) 1.36 1.57 0.03
Apo lipoprotein B (g/l) 1.10 0.84 0.001
Lipoprotein (a) (g/l) 0.45 0.34 NS
Immunological proﬁle
CIK (g/l) 34.09 38.69 NS
C3 (g/l) 1.09 0.94 0.03
C4 (g/l) 0.18 0.13 0.02
ANA positivity (n, %) 16 76.2 32 76.2 NS
ANUC (UI/ml) 121.69 125.96 NS
ENA positivity (n, %) 14 66.7 28 66.7 NS
Ro positivity (n, %) 10 47.6 24 57.1 NS
La positivity (n, %) 2 9.5 6 14.3 NS
Sm positivity (n, %) 8 38.1 10 23.8 NS
RNP positivity (n, %) 10 47.6 12 28.6 0.06
Anti-dsDNA (UI/ml) 86.31 104.40 NS
ACLA IgG positivity (n, %, mean) 5 23.8 28.87 5 11.9 9.49 0.06
ACLA IgM positivity (n, %, mean) 2 9.5 6.97 5 11.9 6.13 NS
LCR positivity (n, %, mean) 5 23.8 0.81 5 11.9 0.50 0.06
Intima-media thickness
Mean IMT (mm) 0.59 0.55 0.07
Medication
Methylprednisone (mg/day) 6.04 30.89 NS
Total methylprednisone (g) 21.42 12.09 NS
Cumulative dose of azathioprine (g) 50.43 44.01 NS
Cumulative dose of hydroxychloroquine (g) 119.87 235.18 NS
Cumulative dose of cyclosporine A (g) 76.64 75.22 NS
Cumulative dose of cyclophosphamide (g) 3.62 1.768 0.03
Cumulative dose of salazopyrine (g) 0 0.71 NS
Cumulative dose of mycophenolate mofetil (g) 122.86 28.74 NS
Cumulative dose of methotrexate (g) 0.19 0.25 NS
Use of statins (n, %) 9 42.3 4 9.5 <0.001
Use of ACEi (n, %) 11 52.3 19 45.2 NS
Use of warfarin (n, %) 13 61.9 3 7.1 <0.001
Use of LMWH (n, %) 6 28.6 2 4.3 0.03
Use of acetylsalicylic acid (n, %) 9 42.3 14 3.3 NS
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of physical activity. Closer relationship was demonstrated
between the history of MI on one hand and high levels of
apolipoprotein B and LDL on the other ( p < 0.001).
Patients with a history of cerebrovascular disease (n = 8)
Patients with a history of cerebrovascular disease were mostly
men ( p = 0.02), diabetics ( p = 0.01), and obese people ( p = 0.04).Lipid spectrum alterations were not signiﬁcant here, while
apolipoprotein B levels showed some tendency toward higher
values and so did hsCRP concentrations.
Patients with a history of thromboembolic disease (n = 12)
Patients with a history of TE have high levels of anticardiolipin
antibodies ( p = 0.03) and lower level of physical activity
( p = 0.05), these differences being statistically signiﬁcant.
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alterations concerning all evaluated parameters, with the
highest signiﬁcance for low levels of apolipoprotein A-1
( p < 0.001). The above subgroup of patients also had a higher
cumulative impairment according to SLICC ( p = 0.05).
Conclusion
In this article, we present the results of cross-sectional and
retrospective follow-up of patients in a single center. The
number of patients in our study was relatively small. We are
thus aware that the possibilities of interpretation of our data
are limited. However, the prevalence of cardiovascular
diseases was quite high (30%) despite the fact that the mean
age of our patients was about 38 years. Several signiﬁcant
factors associated with cardiovascular events were detected,
one of them being obesity (no matter whether quantiﬁed by
BMI or by waist circumference). Smoking or its quitting less
than 5 years previously was also related to higher incidence of
cardiovascular events. Lipid spectrum corresponded to high-
risk proﬁle in patients with cardiovascular disease. As for HDL
cholesterol values, patients with cardiovascular disease and
not differ signiﬁcantly from those without such a disease;
however, normal HDL values do not guarantee low cerebro-
vascular risk since the HDL molecule can undergo a pro-
inﬂammatory transformation. Patients with a history of
thromboembolic event had a signiﬁcantly lower level of
physical activity. As for the medication, we failed to demon-
strate signiﬁcantly higher daily or cumulative doses of
glucocorticoids in hypertonic patients with cardiovascular
disease. It seems necessary to establish a multicentric,
prospective cohort of SLE patients to make valid evaluation
of cardiovascular risk changes possible; it would also help to
establish the risk factors for cardiovascular disease associated
with accelerated atherosclerosis or with thromboembolic
disease.
Atherosclerosis is a disease with multifactorial etiology; in
the past years, it has become increasingly clear that immune-
mediated inﬂammation of vascular wall plays a crucial role in
its pathogenesis. This theory is supported by the presence of
macrophages, activated lymphocytes, and other inﬂammatory
components in atherosclerotic plaques. It is also known that
any inﬂammatory process, no matter whether infectious,
autoimmune or of other origin, accelerates the development of
atherosclerosis in different ways. The development of athero-
sclerosis in SLE is associated not only with more common
presence of traditional risk factors for atherogenesis (obesity,
smoking, metabolic syndrome) but also with SLE-speciﬁc
factors.
Relative risk (RR) of accelerated atherosclerosis in SLE is 7.1,
i.e. up to 50 times higher in young women with SLE than in a
healthy population of the same age; RR of myocardial
infarction and cerebrovascular accident is 2.27 and 2.05 times
higher, respectively [8]. Metabolic syndrome affects up to 32%
of SLE patients [15]. When taking into account the information
about SLE prevalence in Europe and in the USA, the estimated
number of SLE patients in the Czech Republic would be 6–10
thousands [15]. This substantial number of patients, often
quite young, has an increased risk of cardiovascular events.In LUMINA (a multicentric, multiethnical registry), based on
prospective follow-up of 637 SLE patients, 1-year incidence of
cardiovascular diseases, myocardial infarctions, and cerebro-
vascular accidents was found to be 6.2%, 2%, and 2.8%,
respectively [16]. According to results concerning a Canadian
prospective cohort of 1249 patients, the incidence of cardio-
vascular diseases, myocardial infarctions, and cerebrovascular
accidents was 5.7%, 1.1%, and 1.8%, respectively [17]. Groups at
higher risk in both cohorts comprised white patients, males,
people with later-onset SLE, obese individuals, smokers,
hypertonics, and individuals with a family history of cardio-
vascular disorders. Higher risk was associated with positivity
of anticardiolipin antibodies, hsCRP, and higher damage index
(SLICC) at the beginning of follow-up [16,17]. Compared with
general population it is a high prevalence of cardiovascular
disease and risk factors. For example, in the Czech study POST-
MONICA, 3612 individuals were monitored for cardiovascular
risks. Obesity was found in 32.4% of males and 28.3% females.
The prevalence of smoking was 31.9% for men and 23.3% for
women. The prevalence of hypertension (47.8% of males and
36.6% of females) was high. Diabetes was detected in 9.4% of
males and 4.7% of females [18].
Glucocorticoids, which are very widely used in SLE, exert a
crucial metabolic effect. In predisposed individuals, they cause
impaired glucose tolerance or diabetes; they also increase
blood pressure and weight by 4–8%, leading to fat deposition in
the risky abdominal parts. Likewise, they change the lipid
spectrum, thus accelerating the development of atherosclero-
sis. The general relative risks of heart failure, myocardial
infarction, cerebrovascular accident/transitory ischemic at-
tack, and death are 3.7, 3.3, 1.7, and 7.4, respectively. The risk of
these outcomes depends on the daily dose. According to
Madger, who analyzed a large cohort comprising 1874 patients,
the use of glucocorticoids represents a signiﬁcant risk factor
for the development of cardiovascular events. Prednisone
doses of 10–19 mg daily are associated with a relative risk (RR)
of cardiovascular events equal to 2.4, while doses of 20 mg and
higher increase the risk up to 5.1 times [19]. Doses below 7.5 mg
do not increase the cardiovascular risk; on the contrary, they
can be protective thanks to the predominance of their anti-
inﬂammatory effects [20,21].
Lipidogram can be negatively inﬂuenced by certain other
immunosuppressants, too. Metabolic effects comprising glu-
cose tolerance impairment are described in about 5% of
patients treated with cyclosporine A, this drug also being
responsible for arterial hypertension or its acceleration. Some
1–10% of patients using cyclosporine A will suffer a myocardial
infarction [22]. Cyclophosphamide and methotrexate are – in
about 1% of cases – associated with veno-occlusive thrombo-
embolic events concerning mostly peripheral vessels and with
myocardial infarctions. We have to add, however, that these
risks are similarly present during treatment for other diagno-
ses and that immunosuppressants are given in smaller doses
in rheumatology compared to that in, for example, oncology
[23].
According to the current guidelines, adequate attention has
to be paid to timely detection of atherosclerosis in SLE. Based
on EULAR (European League Against Rheumatism) guidelines
and on the published indicators of quality of care for SLE
patients, the Czech Society for Rheumatology recommends to
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of SLE is made but also during the follow-up of SLE patients
[24–26]. Prevention and therapy of traditional risk factors are,
in principle, the same as in the general population [12]. It is
necessary to assess the family history, cardiovascular disease
in personal history, smoking, and the level of physical activity.
We have to look for hypertension and – if present – to treat and
monitor it in an adequate manner. The basic measures also
include lipid spectrum and glycemia monitoring and the aim
to minimize the glucocorticoid dose [26].
Evaluation of early atherosclerosis manifestations repre-
sents a problem per se. Ultrasound methods can be used
(intima-media thickness assessment, ﬂow-mediated vasodi-
latation–FMD), with Coronary Artery Calciﬁcation Score (CACS)
calculation or investigations using radioisotopes (Dual Isotope
Myocardial Perfusion Imaging – DIMPI) being the alternatives.
We chose the measurement of carotid IMT in our study. The
results showed a certain trend toward changes in the
incidence of cardiovascular disorders, but the difference failed
to reach statistical signiﬁcance. The interpretations of IMT in
various studies are contradictory; it seems, however, that IMT
changes and measurements of plaque size represent the most
important parameters. As shown in a prospective study in
which 392 female patients with SLE were followed with respect
to the development of cerebrovascular accidents, RR values in
high IMT and in the presence of atherosclerotic plaque were
1.35 and 4.26, respectively [27].
The treatment of systemic lupus erythematosus aims not
only at controlling the active disease, maintaining its remis-
sion, and preventing severe organ damage but also at
preventing secondary complications and solving them. Cor-
rect interpretation of many clinical symptoms and laboratory
ﬁndings is crucial, and so are systematic prevention and
therapy of SLE relapses and complicating infections plus
effective minimization of adverse treatment effects and of
chronic inﬂammatory process. SLE is a disease with heteroge-
neous clinical picture, often demanding a highly individual-
ized therapeutic approach. The care for SLE patients is very
complex and multidisciplinary; it is crucial to prevent the
adverse effects of treatment and to choose well any preventive
measures – including those aimed at later-onset disease
manifestations such as cardiovascular events. Our goal was to
contribute to the discussion about cardiovascular problems in
SLE and to point out the high rate of cardiovascular disorders
and certain risk factors. We hope that this study will form a
basis for a prospective cohort comprising SLE patients that
will make it possible to follow-up various aspects of SLE in
time.
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